A detailed history of Geode Capital Management, LLC transactions in Entrada Therapeutics, Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 576,451 shares of TRDA stock, worth $9.86 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
576,451
Previous 529,939 8.78%
Holding current value
$9.86 Million
Previous $7.55 Million 22.06%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$13.65 - $17.86 $634,888 - $830,704
46,512 Added 8.78%
576,451 $9.22 Million
Q2 2024

Aug 09, 2024

BUY
$11.85 - $16.45 $646,784 - $897,857
54,581 Added 11.48%
529,939 $7.55 Million
Q1 2024

May 13, 2024

BUY
$11.58 - $17.0 $185,013 - $271,609
15,977 Added 3.48%
475,358 $6.74 Million
Q4 2023

Feb 13, 2024

BUY
$11.36 - $16.99 $236,288 - $353,391
20,800 Added 4.74%
459,381 $6.93 Million
Q3 2023

Nov 13, 2023

BUY
$13.61 - $18.01 $516,499 - $683,479
37,950 Added 9.47%
438,581 $6.93 Million
Q2 2023

Aug 11, 2023

BUY
$11.02 - $18.01 $2.39 Million - $3.91 Million
216,841 Added 117.98%
400,631 $6.07 Million
Q1 2023

May 15, 2023

BUY
$9.58 - $16.2 $17,560 - $29,694
1,833 Added 1.01%
183,790 $2.66 Million
Q4 2022

Feb 13, 2023

BUY
$13.52 - $22.89 $200,623 - $339,664
14,839 Added 8.88%
181,957 $2.46 Million
Q3 2022

Nov 14, 2022

BUY
$9.65 - $15.76 $630,598 - $1.03 Million
65,347 Added 64.21%
167,118 $2.63 Million
Q2 2022

Aug 12, 2022

SELL
$5.49 - $12.94 $417,031 - $982,948
-75,962 Reduced 42.74%
101,771 $1.24 Million
Q1 2022

May 13, 2022

BUY
$7.99 - $16.93 $124,212 - $263,193
15,546 Added 9.59%
177,733 $1.67 Million
Q4 2021

Feb 11, 2022

BUY
$13.7 - $35.0 $2.22 Million - $5.68 Million
162,187 New
162,187 $2.78 Million

Others Institutions Holding TRDA

About Entrada Therapeutics, Inc.


  • Ticker TRDA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 31,368,500
  • Market Cap $536M
  • Description
  • Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in precli...
More about TRDA
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.